(A) Effect of treatment on median ADAMTS13 activity and IgG antibody levels in box-whisper format from admission to 1 year of follow-up in the rituximab group. (B) Median ADAMTS13 activity in the trial patients from admission to 1 year of follow-up. (C) Median anti-ADAMTS13 IgG levels in trial patients from admission to 1 year of follow-up. (D) Effect of rituximab on CD19 levels (normal range, 5%-15%) before each rituximab infusion and at follow-up to 1 year. (E) Median ADAMTS13 activity and IgG antibody levels on admission, in remission, and on relapse in the historical group.